Myocardial infarction in progressive muscular dystrophy

Shapiro, Howard S.; Ribeilima, Jose; Wendt, Vernon E.

doi:10.1016/0002-9149(64)90137-7

Cited by 5 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has generally been difficult to associate the accounts of heart disease with specific types of systemic myopathy since the term "progressive muscular dystrophy" has usually been applied as an overall designation without attempting to subdivide patients into the various clinical groups." [10][11][12][13][14][15][16][17][18][19] Furthermore, the different forms of muscular dystrophy resemble each other histologically.9' 20 Biopsy, therefore, cannot be depended upon to separate one from the other. Reviews have been limited by employing retrospective analyses of hospital case records'0 or by depending upon published reports of incompletely classified cases.'…”

mentioning

confidence: 99%

The Cardiomyopathy of Progressive Muscular Dystrophy

1966

View full text Add to dashboard Cite

A prospective study was undertaken in order to examine the histories, physical signs, phonocardiograms, electrocardiograms, vectorcardiograms, X-rays, serum enzymes, pulmonary ventilatory findings, and hemodynamics in a group of 55 patients selected solely on the basis of one of the major types of progressive muscular dystrophy (table 9). The classification included: (1) the classic Duchenne type, (2) the limb girdle type, (3) the facioscapulohumeral type, and (4) a group of patients in whom clinical distinction between benign Duchenne dystrophy and limb girdle dystrophy with pseudohypertrophy could not be made. No patient had recognized heart disease prior to selection. Follow-up periods ranged from a few months to 5 years. The pertinent literature was extensively reviewed. In all groups clinical evidence of heart disease had to be interpreted in the context of the influence of the somatic musculoskeletal defects on "cardiac" symptoms, cardiovascular physical signs, and radiological appearance of the heart. On the other hand, convincing evidence of intrinsic heart disease-subtle to overt-was found in each of the major categories of progressive muscular dystrophy. Detection of cardiomyopathy was simplest and most frequent in the classic Duchenne group because of the highly characteristic features of the scalar electrocardiogram which might direct attention to the systemic myopathy prior to its clinical recognition. However, the presence of heart disease in patients with forms of dystrophy other than the classic Duchenne deserves particular emphasis. Evidence of cardiomyopathy in these latter forms varied from subtle quadruple gallop rhythms in the limb girdle and facioscapulohumeral groups to cardiomyopathic death in the benign Duchenne and limb girdle-pseudohypertrophic group. Currently available information on the heart in muscular dystrophy has as a rule depended upon retrospective studies, upon reviews of published reports of incompletely classified cases, upon discussions of individual cardiovascular features, or upon observations of individual types of dystrophy. The present prospective study was undertaken to obviate some of these shortcomings. Comprehensive assessment of a large and carefully classified group of dystrophic subjects has provided additional information regarding the clinical spectrum of dystrophic cardiomyopathy.

show abstract

mentioning

confidence: 99%

The Cardiomyopathy of Progressive Muscular Dystrophy

1966

View full text Add to dashboard Cite

show abstract

Die Biochemie der progressiven Muskeldystrophie

Heyck

Laudahn

1969

Die Progressiv-Dystrophischen Myopathien

View full text Add to dashboard Cite

Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel

Spurney

Ascheim²,

Charnas

et al. 2021

Open Heart

View full text Add to dashboard Cite

Cardiac disease is now the leading cause of death in Duchenne muscular dystrophy (DMD). Clinical evaluations over time have demonstrated asymptomatic cardiac troponin elevations and acute elevations are associated with symptoms and cardiac dysfunction in DMD. Clinicians require a better understanding of the relationship of symptoms, troponin levels and progression of cardiac disease in DMD. As clinical trials begin to assess novel cardiac therapeutics in DMD, troponin levels in DMD are important for safety monitoring and outcome measures. The Parent Project Muscular Dystrophy convened an expert panel of cardiologists, scientists, and regulatory and industry specialists on 16 December 2019 in Silver Spring, Maryland and reviewed published and unpublished data from their institutions. The panel recommended retrospective troponin data analyses, prospective longitudinal troponin collection using high-sensitivity cardiac troponin I assays, inclusion of troponin in future clinical trial outcomes and future development of clinical guidelines for monitoring and treating troponin elevations in DMD.

show abstract

Myocardial infarction in progressive muscular dystrophy

Cited by 5 publications

References 11 publications

The Cardiomyopathy of Progressive Muscular Dystrophy

The Cardiomyopathy of Progressive Muscular Dystrophy

Die Biochemie der progressiven Muskeldystrophie

Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel

Contact Info

Product

Resources

About